KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Change in Receivables: 2017-2024

Historic Change in Receivables for Aquestive Therapeutics (AQST) over the last 8 years, with Dec 2024 value amounting to -$1.1 million.

  • Aquestive Therapeutics' Change in Receivables fell 101.70% to -$63,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.1 million, marking a year-over-year increase of 86.03%. This contributed to the annual value of -$1.1 million for FY2024, which is 135.60% down from last year.
  • According to the latest figures from FY2024, Aquestive Therapeutics' Change in Receivables is -$1.1 million, which was down 135.60% from $3.1 million recorded in FY2023.
  • Over the past 5 years, Aquestive Therapeutics' Change in Receivables peaked at $5.4 million during FY2021, and registered a low of -$7.4 million during FY2022.
  • Over the past 3 years, Aquestive Therapeutics' median Change in Receivables value was -$1.1 million (recorded in 2024), while the average stood at -$1.8 million.
  • In the last 5 years, Aquestive Therapeutics' Change in Receivables skyrocketed by 186.69% in 2021 and then tumbled by 237.34% in 2022.
  • Over the past 5 years, Aquestive Therapeutics' Change in Receivables (Yearly) stood at -$6.2 million in 2020, then skyrocketed by 186.69% to $5.4 million in 2021, then plummeted by 237.34% to -$7.4 million in 2022, then spiked by 141.80% to $3.1 million in 2023, then plummeted by 135.60% to -$1.1 million in 2024.